68Ga DOTATATE PET/CT in Neuroendocrine Tumors (Expanded Access)

Jonsson Comprehensive Cancer Center

Status

Conditions: Cancers Expressing Somatostatin Receptors; Neuroendocrine Tumors; Carcinoid Cancer; Medullary Thyroid Cancer

Treatments: Drug: 68Ga DOTATATE

Study type: Expanded Access

Funder types: Other

Identifiers

NCT02174679

DOTATATE12-001920EA

JCCCID324 (Other Identifier)

NCI-2016-01796 (Registry Identifier)

Details and patient eligibility

About

To evaluate 68Ga-DOTATATE PET/CT for staging of patients with carcinoid, neuroendocrine tumors, medullary thyroid cancer and other cancers expressing somatostatin receptors.

Full description

This is an expanded access study with a total of 300 participants with NET and suspected SSTR positive tumors. Eligible participants will undergo baseline assessments at enrollment. Study participants will receive 68Ga-DOTATATE and will undergo a PET/CT imaging study. All patients referred by Oncologists will be screened by a UCLA Nuclear Medicine physician and then accepted for scanning if clinically appropriate.

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Older than 18 years the time of radiotracer administration
• Provides written informed consent
• Known diagnosis of NET or suspected SSTR positive tumors Women of childbearing age must have a negative pregnancy test at screening/baseline
• Able to remain still for duration of each imaging procedure (about 30 minutes)

Exclusion criteria

• Less than 18 years-old at the time of radiotracer administration
• Pregnant or nursing
• Inability to complete the needed investigational and standard-of-care imaging examinations due to other reasons (severe claustrophobia, radiation phobia, etc.)
• Any additional medical condition, serious concurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance.